Here, we used CRISPR genome-editing technology and demonstrated that disruption of the PTPRZ gene in human glioma LN-229 cells resulted in profoundly reduced tumor growth in xenografted mice, suggesting that PTPRZ may be a potential therapeutic target for glioma. This evidence concerns the gene PTPRZ1 and central nervous system cancer.